Menu
Shedding Light on the Risks
& Benefits of Medications
Shedding Light on the Risks
& Benefits of Medications The FDA’s Drug Adverse Event Database Is Now Updated in Real Time: Here’s How to Use It
Updates to the FDA’s Adverse Events Reporting System (FAERS) will be more frequent, but they don’t tell the whole story
August 25, 2025
0 Comments
republishon this page:
On Friday, August 22, the Food and Drug Administration (FDA) announced in a press release that it would begin updating its Adverse Events Reporting System (FAERS) in real time, replacing the agency’s previous quarterly update schedule. The agency said the change “demonstrates [the FDA’s] commitment to radical transparency and real-time protection of public health.”
Patients, doctors, and even family members can submit reports directly to the FAERS database if they suspect a symptom is related to a medication. Reports can include both side effects and cases where a medication that once worked no longer seems effective.
To Search The Database
Click the blue search bar at the top of the dashboard and type in the name of the drug you’re interested in. After clicking search, the results will show the number of reactions submitted per year, but not the specific side effects. To view those, use the drop-down menu on the right-hand side above the bar graph and select “cases by reaction.”
To report your experience to FAERS, click here.
FDA scientists routinely monitor the database for patterns of serious side effects or signs of inefficacy that warrant further investigation. Those investigations can lead the agency to add new warnings to medication labels, downgrade a generic drug’s bioequivalence status (meaning it is no longer considered interchangeable with the brand-name drug), or even remove the medication from the market.
While this public, searchable database is useful for keeping track of certain medications, it does not provide a complete or verified picture of a drug’s side effects or safety profile, and individual reports are not independently confirmed. Madris Kinard, who previously worked in post-market safety at the FDA, told STAT that the move was a step in the right direction, but without fuller context on each report, the data may have limited value unless someone is closely monitoring a specific medication.
Want to Share Your Story?
If you’ve experienced side effects or medication issues related to this topic, we want to hear from you.
Submit Your Story- (2025, August 22). FDA Begins Real-Time Reporting of Adverse Event Data. U.S. Food and Drug Administration. Retrieved August 25, 2025
- MedWatch Online Voluntary Reporting Form. (n.d.). FDA.
- Lawrence, L. (2025, August 22). FDA says it will publish reports of adverse events tied to drugs on daily basis. STAT.
DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.
While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.
on this page:
RECOMMENDED:
DONATE:
Help fund our fight for improved medication safety and transparency by supporting our independent journalism.
Give NowWe seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.
Republish This Story for Free
Creative Commons License (CC BY-NC-ND 4.0)MedShadow.org is dedicated to empowering people with our evidence-based journalism about the safest ways to take over-the-counter (OTC) and prescription (Rx) medications.
We also seek to stimulate public discussion about potential improvements to drug research, manufacturing and distribution processes. and also to encourage the improvement of processes to ensure that we are all better protected.
As a result, we encourage other nonprofit newsrooms, mission-aligned outlets, and advocacy organizations to republish our original content under the following conditions:
You May Republish Our Articles for Free If:
1. We Are Credited Fully and Clearly
You must include the byline and credit MedShadow.org as the original publisher. Please include a link to the original article at the top or bottom of the piece. Use the following attribution:
This article was originally published by MedShadow, a nonprofit foundation that focuses on the safest ways to take over-the-counter and prescription medications.
2. Our Content Isn’t Edited Without Permission
You may make small changes for clarity, such as adjusting headlines, subheadings, or transitions, but you may not change the core meaning, tone, or intent of the article. For substantive edits, email us at republish@medshadow.org for review and approval.
3. You Do Not Sell Or Use Our Content Commercially
Our work is free to share, but it may not be sold, monetized, or repurposed for commercial gain. You may not republish our articles behind a paywall or in publications whose primary purpose is advertising or product promotion. You may not place drug or supplement advertising adjacent to our story.
4. Photos, Graphics, and Multimedia Are Not Used Without Permission
Only the text of the article is available for republication. Images, graphics, and videos may not be reused without explicit written permission, unless they are clearly marked as Creative Commons licensed. Contact us if you’d like to request reuse of a visual asset.
You May Not:
- Use our content to promote a product, service, or political candidate
- Republish only part of an article or create derivative works without permission
- Add affiliate links, advertising overlays, or lead generators
- Translate the article without written permission
Contact Us
If you’re unsure whether your intended use falls within these guidelines, or would like to discuss a formal syndication or licensing arrangement, please email: republish@medshadow.org
We want our journalism to reach as many people as possible, especially those making critical decisions about medications and health.
Article HTML
<!-- wp:paragraph -->
<p>On Friday, August 22, the Food and Drug Administration (FDA) announced <a href="https://www.fda.gov/news-events/press-announcements/fda-begins-real-time-reporting-adverse-event-data" target="_blank" rel="noreferrer noopener">in a press release</a> that it would begin updating its Adverse Events Reporting System (FAERS) in real time, replacing the agency’s previous quarterly update schedule. The agency said the change “demonstrates [the FDA’s] commitment to radical transparency and real-time protection of public health.”</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Patients, doctors, and even family members can submit reports directly to the FAERS database if they suspect a symptom is related to a medication. Reports can include both side effects and cases where a medication that once worked <a href="https://medshadow.org/generic-adhd-medication-issues-new-study/?fbclid=IwY2xjawKm121leHRuA2FlbQIxMQBicmlkETFHVFFCRmh6bkZ1YWVmaXRHAR6Go9pjePSuzECknaq72XlUeY6eOgM4aXElppg1se2oDyqX1Y8lGrEOx5Y7hA_aem_xIwQlbpuu-sPzuDbnYZ2WA" target="_blank" rel="noreferrer noopener">no longer seems effective</a>.</p>
<!-- /wp:paragraph --><!-- wp:myplugin/custom-alignment-block {"align":"right"} -->
<div class="wp-block-myplugin-custom-alignment-block alignright"><h2>To Search The Database</h2><p>Click the blue search bar at the top of the <a href="https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis" target="_blank" rel="noreferrer noopener"><strong>dashboard</strong></a> and type in the name of the drug you’re interested in. After clicking search, the results will show the number of reactions submitted per year, but not the specific side effects. To view those, use the drop-down menu on the right-hand side above the bar graph and select “cases by reaction.”</p></div>
<!-- /wp:myplugin/custom-alignment-block --><!-- wp:paragraph -->
<p>To report your experience to FAERS, <a href="https://www.accessdata.fda.gov/scripts/medwatch/index.cfm" target="_blank" rel="noreferrer noopener">click here</a>.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>FDA scientists routinely monitor the database for patterns of serious side effects or signs of inefficacy that warrant further investigation. Those investigations can lead the agency to add new warnings to medication labels, downgrade a <a href="https://medshadow.org/generic-vyvanse-not-working/" target="_blank" rel="noreferrer noopener">generic drug’s bioequivalence status</a> (meaning it is no longer considered interchangeable with the brand-name drug), or even remove the medication from the market.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>While this public, searchable database is useful for keeping track of certain medications, it does not provide a complete or verified picture of a drug’s side effects or safety profile, and individual reports <a href="https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard" target="_blank" rel="noreferrer noopener">are not independently confirmed</a>. <a href="https://www.linkedin.com/in/madris/" target="_blank" rel="noreferrer noopener">Madris Kinard</a>, who previously worked in post-market safety at the FDA, told <a href="https://www.statnews.com/2025/08/22/fda-faers-drugs-adverse-events/?utm_campaign=pharmalittle&utm_medium=email&_hsenc=p2ANqtz-_8IVoo5HiUjUdjf2WTlOPG9wFZo-n6yV-XIWyP4uyn6NFOfmG9YqQ0GfpGu2zCCnaYKIQvI1hceDSQ5k9Xr15JRxd9Zw&_hsmi=377400854&utm_content=377400854&utm_source=hs_email" target="_blank" rel="noreferrer noopener">STAT</a> that the move was a step in the right direction, but without fuller context on each report, the data may have limited value unless someone is closely monitoring a specific medication.</p>
<!-- /wp:paragraph -->